1. Home
  2. VRTX vs TTE Comparison

VRTX vs TTE Comparison

Compare VRTX & TTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • TTE
  • Stock Information
  • Founded
  • VRTX 1989
  • TTE 1924
  • Country
  • VRTX United States
  • TTE France
  • Employees
  • VRTX N/A
  • TTE N/A
  • Industry
  • VRTX EDP Services
  • TTE Oil & Gas Production
  • Sector
  • VRTX Technology
  • TTE Energy
  • Exchange
  • VRTX Nasdaq
  • TTE Nasdaq
  • Market Cap
  • VRTX 115.6B
  • TTE 138.3B
  • IPO Year
  • VRTX 1991
  • TTE 1991
  • Fundamental
  • Price
  • VRTX $462.13
  • TTE $59.16
  • Analyst Decision
  • VRTX Buy
  • TTE Buy
  • Analyst Count
  • VRTX 25
  • TTE 5
  • Target Price
  • VRTX $509.00
  • TTE $65.20
  • AVG Volume (30 Days)
  • VRTX 1.1M
  • TTE 1.4M
  • Earning Date
  • VRTX 08-04-2025
  • TTE 07-24-2025
  • Dividend Yield
  • VRTX N/A
  • TTE 4.42%
  • EPS Growth
  • VRTX N/A
  • TTE N/A
  • EPS
  • VRTX N/A
  • TTE 5.49
  • Revenue
  • VRTX $11,099,700,000.00
  • TTE $187,119,000,000.00
  • Revenue This Year
  • VRTX $10.43
  • TTE $6.61
  • Revenue Next Year
  • VRTX $10.81
  • TTE N/A
  • P/E Ratio
  • VRTX N/A
  • TTE $10.17
  • Revenue Growth
  • VRTX 8.98
  • TTE N/A
  • 52 Week Low
  • VRTX $377.85
  • TTE $52.78
  • 52 Week High
  • VRTX $519.88
  • TTE $70.50
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 49.57
  • TTE 38.18
  • Support Level
  • VRTX $460.55
  • TTE $59.35
  • Resistance Level
  • VRTX $474.76
  • TTE $61.72
  • Average True Range (ATR)
  • VRTX 9.12
  • TTE 0.87
  • MACD
  • VRTX -1.34
  • TTE -0.34
  • Stochastic Oscillator
  • VRTX 28.52
  • TTE 10.16

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About TTE TotalEnergies SE

TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2024, it produced 1.5 million barrels of liquids and 5.2 billion cubic feet of natural gas per day. At the end of 2024, reserves stood at 11.1 billion barrels of oil equivalent, 54% of which are liquids. During 2024, it had LNG sales of 39.8 million metric tons. The company owns interests in refineries with a capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. At year-end, its gross installed renewable power generation capacity was 26 gigawatts.

Share on Social Networks: